Articles

Sprint Bioscience summarises below its upcoming meetings with potential partners and investors. International partnering and investor conferences: 18-19 September: Nordic Life Science Days, Malmö, Sweden 8-9 October: LSX Nordic Congress, Copenhagen, Denmark 4-6 November: BIO-Europe Stockholm, Sweden 20-21 November: BioStock Life Science Summit

The Bio International Convention partnering conference was held 3-6 June in San Diego, California. Sprint Biosciences CEO Johan Emilsson was there. What general impressions do you take home from the conference?"There is almost always high pressure at this conference. It is one of the largest and most prestigious partnering conferences in biotechnology and drug development with...

Sprint Bioscience summarises below its upcoming meetings with potential partners and investors. International partnering and investor conferences: 18-20 March 2024: BIO-Europe Spring, Barcelona, Spain 29-30 April 2024: LSX World Congress, London, England 3-6 June 2024: BIO International Convention, San Diego, USA 

Following the press release on 15 December regarding the Vps34 programme, Redeye's analysts put some questions to Sprint Biosciences' CEO, Johan Emilsson. The interview is also available at Redeye. Why is Deciphera returning the programme? According to the agreement, they have the right to return the programme without specifying any reason and they have chosen not to go public with the reason. May this...

Johan Emilsson, newly appointed CEO of Sprint Bioscience, answers questions #femsnabba at Börsvärlden about the company's success in a tough, competitive market. The company is driven by demonstrating how effective drug development can be with the right attitude and expertise, and by improving the lives of those affected by cancer. Johan Emilsson, you are the new CEO of Sprint Bioscience since...

See what has been written about Sprint Bioscience regarding the news of the VADA agreement: Fierce BiotechDaily IndustryBusiness WorldBioStock Börsronden v 33Pharmaceutical market - industry coverage from Dagens MedicinLifeScience SwedenNordic Life Science News

Sprint Biosciences acting CEO Mathias Skalmstad visited Redeye's studio and answered questions regarding the licence agreement for the VADA programme. Press releaseComment from Redeye on the agreement